LifeMD, Inc. (NASDAQ:LFMD) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of LifeMD, Inc. (NASDAQ:LFMD) have been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating and eight have issued a buy rating on the company. The average 1-year price target among brokers that have covered the stock in the last year is $7.5714.

A number of research firms have issued reports on LFMD. BTIG Research reduced their price target on shares of LifeMD from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Lake Street Capital set a $5.00 price objective on shares of LifeMD in a report on Thursday, August 6th. Mizuho set a $7.00 target price on shares of LifeMD in a research report on Thursday, August 6th. Wall Street Zen cut shares of LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Finally, B. Riley Financial decreased their price target on shares of LifeMD from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th.

LifeMD Trading Down 1.5%

NASDAQ:LFMD opened at $3.27 on Friday. The company has a market cap of $157.61 million, a PE ratio of -65.39 and a beta of 2.02. The company has a 50 day simple moving average of $4.19 and a two-hundred day simple moving average of $3.96. LifeMD has a 12 month low of $2.56 and a 12 month high of $7.32.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). The firm had revenue of $47.28 million during the quarter, compared to analysts’ expectations of $49.16 million. LifeMD had a negative return on equity of 168.23% and a net margin of 0.10%. Research analysts forecast that LifeMD will post -0.48 earnings per share for the current year.

Institutional Investors Weigh In On LifeMD

Several hedge funds and other institutional investors have recently modified their holdings of LFMD. Federated Hermes Inc. grew its holdings in LifeMD by 278.1% during the fourth quarter. Federated Hermes Inc. now owns 980,285 shares of the company’s stock valued at $3,343,000 after purchasing an additional 721,018 shares during the period. Prescott Group Capital Management L.L.C. bought a new position in shares of LifeMD in the fourth quarter worth about $2,344,000. Arrowstreet Capital Limited Partnership raised its stake in shares of LifeMD by 1,767.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 434,937 shares of the company’s stock worth $5,924,000 after buying an additional 411,651 shares during the period. JPMorgan Chase & Co. lifted its position in shares of LifeMD by 581.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 412,571 shares of the company’s stock valued at $5,619,000 after buying an additional 352,004 shares in the last quarter. Finally, Whetstone Capital Advisors LLC lifted its position in shares of LifeMD by 89.6% during the 4th quarter. Whetstone Capital Advisors LLC now owns 703,053 shares of the company’s stock valued at $2,397,000 after buying an additional 332,269 shares in the last quarter. 35.52% of the stock is currently owned by hedge funds and other institutional investors.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.